WATER研究:Aquablation与经尿道前列腺电切术治疗良性前列腺增生的双盲随机对照试验
WATER研究为双盲、多中心、前瞻性随机对照试验,纳入181例中重度下尿路症状的良性前列腺增生患者,比较Aquablation与经尿道前列腺电切术(TURP)。主要疗效终点为6个月国际前列腺症状评分(I-PSS)下降,非劣效假设成立;主要安全终点发生率Aquablation组26%低于TURP组42%,达非劣效并显示优效性(p=0.0149);性活跃男性中Aquablation组无射精率10%低于TURP组36%(p=0.0003)。
要点
- Aquablation在6个月I-PSS改善方面非劣效于TURP。
- Aquablation主要安全终点发生率26%,低于TURP的42%。
- 性活跃男性无射精率Aquablation 10% vs TURP 36%。
核心结论
- Aquablation手术切除前列腺在症状缓解方面非劣效于经尿道前列腺电切术,且性功能障碍风险更低。
- 较大前列腺(50至80 ml)显示出更明显的安全性和有效性优势。
研究设计与样本
- 双盲、多中心、前瞻性、随机对照试验,纳入181例与良性前列腺增生相关的中重度下尿路症状患者,随机接受经尿道前列腺电切术或Aquablation。
主要发现
- 平均总手术时间Aquablation与经尿道前列腺电切术相似(33 vs 36分钟,p=0.2752),但切除时间Aquablation更低(4 vs 27分钟,p<0.0001)。
- 6个月时两组I-PSS均大幅改善,预设的非劣效假设成立(p<0.0001)。
- Aquablation组26%、经尿道前列腺电切术组42%发生主要安全终点,达到非劣效并显示优效性(p=0.0149)。
- 性活跃男性中无射精率Aquablation组10%,经尿道前列腺电切术组36%(p=0.0003)。
关键数值与推荐
- 主要疗效终点为6个月国际前列腺症状评分(I-PSS)下降。
- 主要安全终点为Clavien-Dindo持续1级或2级及以上手术并发症。
- 非劣效性检验p<0.0001,优效性检验p=0.0149。
临床怎么用
- Aquablation可作为良性前列腺增生手术治疗的选项,尤其适用于关注性功能保留的患者。
- 对于前列腺体积50至80 ml的患者,Aquablation可能带来更明显的安全性和有效性优势。
局限性
- 需要更长期随访评估Aquablation的临床价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We compared the safety and efficacy of Aquablation and transurethral prostate resection for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. MATERIALS AND METHODS: In a double-blind, multicenter, prospective, randomized, controlled trial 181 patients with moderate to severe lower urinary tract symptoms related to benign prostatic hyperplasia underwent transurethral prostate resection or Aquablation. The primary efficacy end point was the reduction in International Prostate Symptom Score at 6 months. The primary safety end point was the development of Clavien-Dindo persistent grade 1, or 2 or higher operative complications. RESULTS: Mean total operative time was similar for Aquablation and transurethral prostate resection (33 vs 36 minutes, p = 0.2752) but resection time was lower for Aquablation (4 vs 27 minutes, p <0.0001). At month 6 patients treated with Aquablation and transurethral prostate resection experienced large I-PSS improvements. The prespecified study noninferiority hypothesis was satisfied (p <0.0001). Of the patients who underwent Aquablation and transurethral prostate resection 26% and 42%, respectively, experienced a primary safety end point, which met the study primary noninferiority safety hypothesis and subsequently demonstrated superiority (p = 0.0149). Among sexually active men the rate of anejaculation was lower in those treated with Aquablation (10% vs 36%, p = 0.0003). CONCLUSIONS: Surgical prostate resection using Aquablation showed noninferior symptom relief compared to transurethral prostate resection but with a lower risk of sexual dysfunction. Larger prostates (50 to 80 ml) demonstrated a more pronounced superior safety and efficacy benefit. Longer term followup would help assess the clinical value of Aquablation.
引用
- Gilling P, Barber N, Bidair M, et al. WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. J Urol. 2018. PMID: 29360529. doi:10.1016/j.juro.2017.12.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。